Special Issue

MRI-Guided Real-Time Adaptive Radiotherapy

Message from the Guest Editor

Precision radiotherapy is the new paradigm of this non-invasive cancer treatment. Over the last years, the concrete evolution in intensity-modulated adaptive radiotherapy was the clinical integration in the treatment room of online MRI with external beam radiotherapy. The advantages of MRI over CT-based images are well known and include higher soft tissue discrimination, the capability to monitor tumor motion, and the possibility of real-time treatment adaptation strategies. MRI-based physiologic information and biomarkers could potentially be utilized and integrated in an advanced-precision radiation therapy strategy: the outcome assessment using image texture represents the emerging world called "radiomics". The integration of MRI imaging capabilities with modern linear accelerators represents a paradigm shift in radiation therapy due to the opportunity to use the real-time anatomic and physiologic changes in tumors and surrounding critical organs to optimize the therapeutic ratio. I look forward to receiving your contributions.

Guest Editor

Prof. Dr. Filippo Alongi

1. Advanced Radiation Oncology Department, Cancer Care Center, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Verona, Italy
2. Department of Medical, Surgical and Health Care Specialties, University of Brescia, 25121 Brescia, Italy

Deadline for manuscript submissions

closed (15 November 2024)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/170618

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)